Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463510 | 0.91 | PRKAA2 (0.47) | PRKAA2MEN1EGFRPRKAB2PRKAG1 | |
| SCHEMBL5469220 | 0.90 | MEN1 (0.55) | PRKAA2MEN1KMT2APRKAB2PRKAG1 | |
| SCHEMBL5330700 | 0.89 | EGFR (0.45) | PRKAA2MEN1KMT2AEGFR | |
| SCHEMBL5465688 | 0.89 | EGFR (0.42) | PRKAA2MEN1KMT2AEGFR | |
| SCHEMBL5469705 | 0.89 | HTR2B (0.49) | PRKAA2EGFR | |
| SCHEMBL5462750 | 0.88 | EGFR (0.43) | PRKAA2MEN1KMT2AEGFRACKR3 | |
| SCHEMBL5462805 | 0.88 | PRKAA2 (0.42) | PRKAA2MEN1KMT2AEGFRPRKAB2 | |
| SCHEMBL5463988 | 0.88 | EGFR (0.43) | PRKAA2EGFRACKR3 | |
| SCHEMBL5462901 | 0.87 | DCLK1 (0.48) | EGFRPRKAA1 | |
| SCHEMBL5464195 | 0.85 | MEN1 (0.52) | PRKAA2MEN1KMT2AEGFRACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | PRKAA2 4108/4885MEN1 4261/4885KMT2A 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.